Munguva pfupi yapfuura, Ascentage Pharma yakazivisa kuti mushonga wayo mutsva weBcl-2 selective inhibitor lisaftoclax (APG-2575) wabvumidzwa neNational Medical Products Administration (NMPA) yekurapa varwere vakuru vane chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) avo vakambogamuchira kanenge kamwe chete kekurapa kunosanganisira Bruton's tyrosine kinase (BTK) inhibitors, izvo zvinoita kuti lisaftoclax ive mushonga wekutanga weBcl-2 inhibitor unogamuchira mvumo yekurapa varwere vane CLL/SLL muChina, uye wechipiri weBcl-2 inhibitor wakabvumidzwa pasi rose.
Lisaftoclax mushonga mutsva, unopihwa nemuromo nemuromo une mamorekuru madiki eBcl-2 anosarudza mushonga wakagadzirwa neAscntage Pharma kurapa varwere vane marara nekudzivisa puroteni yeBcl-2 inodzivirira marara uye nekudaro kudzoreredza maitiro akajairika eapoptosis mumasero ekenza. Mumiedzo yekiriniki, lisaftoclax yakaratidza mikana yakakura yekurapa marara akawanda eropa uye mabundu akaoma, kunyanya muCLL/SLL, zvese sekurapa kumwe chete uye musanganiswa.
Kubvumidzwa uku kwakavakirwa pamhedzisiro yeongororo inokosha yePhase II (APG2575CC201) yakagadzirirwa kuongorora kushanda uye kuchengetedzeka kweLisaftoclax monotherapy muvarwere vane CLL/SLL yakadzokera shure kana kuti isingashande, ine huwandu hwemhinduro (ORR) semhedzisiro huru. Lisaftoclax yakaratidza kushanda kwakanaka uye ORR yakasangana nemhedzisiro yakatarwa muvarwere vakamborapa neBTK inhibitors uye/kana immunochemotherapy. Uyezve, Lisaftoclax yakaratidza kuchengetedzeka kwakanaka pasina tumor-lysis syndrome (TLS) yakaitika panguva yekudzidza, kuwanda kwezvirwere zveropa kwakaderera kwaigoneka, uye kuwanda kwezvirwere zvisiri zveropa zvaive zvakanyanya giredhi 1-2.
CLL/SLL chirwere cheropa chinokonzerwa nemapundu emasero eB akura. Chinonyanya kubata vanhu vakwegura vane zvirwere zvitsva zvinopfuura 100,000 zvinoshumwa pasi rose gore rega rega1. MuChina, uko huwandu hwevanhu vane CLL/SLL hwakaderera pane hwenyika dzekumadokero, chirwere ichi chiri kuitika nekukurumidza, nezera diki rekutanga uye hukasha hwakanyanya2. Senzira yekutanga yekurapa CLL/SLL, ma BTK inhibitors akavandudza zvakanyanya mhedzisiro yekurapa kwevarwere. Zvisinei, ma BTK inhibitors achiri kutarisana nematambudziko akasiyana-siyana akadai sekukwanisa kushoma kukurudzira mhinduro dzakadzika, njodzi huru yekudzokazve mukurapwa kwepakati nepakati uye kwenguva refu, chepfu uye kusashivirira kunoenderana nekurapwa kwenguva refu; nokudaro, kudiwa kwenzira dzakachengeteka uye dzinoshanda dzekurapa kwevarwere vane CLL/SLL.
Kuunzwa kweBcl-2 inhibitors kwakachinja zvakanyanya kurapwa kweCLL/SLL. Apoptosis suppressor factor Bcl-2, inowanzo shandiswa zvakanyanya muzvirwere zvakasiyana-siyana zveropa, kunyanya CLL/SLL, inzira huru iyo masero egomarara anonzvenga apoptosis. Zvisinei, kuwanikwa kweBcl-2 inhibitor senzira yekurapa kwakaoma zvikuru nekuti mashandiro ayo akavakirwa pakudyidzana kweprotein-protein (PPI). Kubatana kweBcl-2 kwakakura, zvichiita kuti zviomere kuti madiki-molecule inhibitors aite zvinodzivirira. Pamusoro pezvo, Bcl-2 protein iri pamitochondria, ine chimiro che double-membrane, ndeimwe yezvikamu zvakaoma uye zvinonetsa zvemasero sezvo ichida kuti mishonga itange yapinda mu cell membrane isati yakwanisa kushanda pa mitochondrial membrane. Izvi zvisati zvaitika, hapana Bcl-2 inhibitor yakanga yabvumidzwa kurapa CLL/SLL muChina. Kubvumidzwa uku kwelisaftoclax kunozadza mukaha wekurapa muCLL/SLL, zvichiunza tariro itsva kuvarwere vazhinji munyika.
Parizvino, kuchine miedzo yakawanda yekiriniki yehunyanzvi hutsva hwekurwisa gomarara muChina huri kutsvaga varwere. Kana muchida kubvunzana nezvemishonga mitsva netekinoroji, munogona kubata Dhipatimendi reBeijing South Region Oncology Hospital International.
Nhamba yefoni: 4008803716
Email：myimmnet@163.com
Nguva yekutumira: Chikunguru-15-2025